title: Minimizing matrix effects in the development of a method for the determination of salmeterol in human plasma by LC/MS/MS at low pg/mL concentration levels.
abstract: Salmeterol is an inhaled bronchodilator drug used for treatment of asthma. Its concentrations in plasma are very low or undetectable by previously developed methods. The present paper describes a method for analysis of salmeterol in human plasma with 2.5 pg/mL lower limit of quantitation. Despite the basic character of the drug the method uses mixed mode anion-exchange solid phase extraction for sample preparation combined with a column switching approach to minimize matrix effects. Samples are separated and detected by LC/MS/MS. The method is easy to use, only requires 0.5 mL of plasma and was validated for use in bioanalytical applications. The method does not suffer from interference from co-administered fluticasone propionate.
authors.affiliation: Tandem Labs, 1121 East 3900 South, Salt Lake City, UT 84124, USA. vladimir@tandemlabs.com
authors.forename: Vladimír
authors.initials: V
authors.lastname: Cápka
authors.forename: Spencer J
authors.initials: SJ
authors.lastname: Carter
mesh_terms: D000318:Adrenergic beta-Agonists / Q000097:blood*; D000420:Albuterol / Q000031:analogs & derivatives* / Q000097:blood; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D000068299:Salmeterol Xinafoate; D012680:Sensitivity and Specificity; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods; D053719:Tandem Mass Spectrometry / Q000379:methods*
chemical_list: D000318:Adrenergic beta-Agonists; D000068299:Salmeterol Xinafoate; D000420:Albuterol